BioMatrix Named as a Preferred Provider for AscellaHealth

BioMatrix Specialty Pharmacy is now included as a preferred provider in AscellaHealth’s home infusion pharmacy network.

BioMatrix Specialty Pharmacy is now included as a preferred provider in AscellaHealth’s home infusion pharmacy network.

AscellaHealth, a global specialty pharmacy and healthcare solutions company, has launched a site of care optimization strategy designed to cut costs for third-party payers without compromising quality of care, BioMatrix said in a news release.

BioMatrix was included in AscellaHealth’s network to “help the organization achieve its goals of improving drug affordability; increasing price transparency; reducing disparities in quality of care and safety; enabling care delivery in the highest-quality, lowest-cost care setting; and increasing patient convenience,” BioMatrix said.

“By selecting top pharmacies for preferred status, we are taking an important step toward reducing the cost of specialty biologic medications and encouraging patients to move from higher-cost settings, like big hospitals and institutions, to lower-cost settings such as physician’s in-office infusion suites or stand-alone infusion centers,” said Dea Belazi, president and CEO of AscellaHealth.

“As part of our mission to help our clients better manage the high costs of specialty medication, this initiative exemplifies our efforts to increase care accessibility by encouraging the use of clinically appropriate, lower-cost care settings,” Belazi added.

Determining the optimal site of care for patients to receive therapy is an important component of treatment success, according to BioMatrix. The company can administer infusions in-home with assistance from one of its nurses, in-office, or at an ambulatory infusion center.

“Our shared focus on positive outcomes for all patients, reduced cost, and price transparency will help AscellaHealth’s members effectively manage their specialty infusion spend without compromising quality care,” said Ken Trader, vice president of Managed Markets at BioMatrix.